Reshma Kewalramani, CEO of Vertex, has described Britain’s approval of Casgevy and the first regulatory approval of a CRISPR-based therapy in the world, as a historic day for medicine and science.
Janelle Nanos tells the success story of Vertex Chief Executive Officer Reshma Kewalramani: from transplant nephrologist to heading biotech giant Vertex.